Peter Webborn

Pete Webborn has over 20 years of experience of drug discovery in the pharmaceutical industry. He has worked in the UK, US and Sweden. His particular areas on interest include prediction of PK properties from in vitro data, physicochemical properties as determinants of PK parameters and hepatic uptake transporters as modulators of drug disposition. He obtained his PhD from the University of Wales, Cardiff and is currently leading the Pharmacokinetics and Mass Spectrometry Imaging group at AstraZeneca. He was a recipient of the Royal Society of Chemistry, Malcolm Campbell medal in 2013 for his work on the discovery of Brilinta.